WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

Acquisition

Olympus pays $270M for BioProtect's prostate balloon spacer

MedDevice Startups Staff · May 26 · 2 min read · Via MedTech Dive

Olympus agreed on May 26, 2026 to acquire BioProtect, an Israeli company, for $270 million, with closing expected by the end of the second quarter of 2026.

BioProtect makes a biodegradable balloon spacer implanted between the prostate and surrounding tissue during radiation therapy for prostate cancer. It degrades on its own after treatment. The device was commercially introduced in 2023 and has been used in more than 11,000 procedures worldwide. BioProtect had about 130 employees and roughly $14.5 million in 2025 revenue.

Olympus said the deal helps it grow in therapeutic areas adjacent to endoscopy, including gastrointestinal and urological care, and that its global distribution and provider relationships would widen patient access. The multiple, close to 19 times trailing revenue, says what a strategic will pay for a single-product company with real procedure volume in a category it wants to enter.

Questions & Answers

How much is Olympus paying for BioProtect?

$270 million, announced May 26, 2026, with closing expected by the end of the second quarter of 2026.

What does BioProtect's device do?

It is a biodegradable balloon spacer implanted between the prostate and surrounding structures during radiation therapy for prostate cancer, protecting healthy tissue and then degrading on its own. It launched commercially in 2023 and has been used in more than 11,000 procedures.

How big was BioProtect before the deal?

About 130 employees and roughly $14.5 million in revenue in 2025, which puts the $270 million price near 19 times trailing revenue.

← Back to M&A